Valneva SE (VLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Valneva SE (VLA) has a cash flow conversion efficiency ratio of -0.058x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.43 Million ≈ $-5.18 Million USD) by net assets (€76.70 Million ≈ $89.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VLA equity financing ratio to measure how much of total assets are equity-financed.
Valneva SE - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Valneva SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Valneva SE (VLA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Valneva SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valneva SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marcopolo S.A
SA:POMO3
|
0.205x |
|
Hunan Huasheng Co Ltd
SHG:600156
|
0.086x |
|
Sampoerna Agro Tbk
JK:SGRO
|
0.034x |
|
Hangzhou Gaoxin Rubber & Plastic Materials Co Ltd
SHE:300478
|
-0.422x |
|
Regal Partners Global Investments Limited
AU:RG1
|
0.038x |
|
Menivim The New REIT Ltd
TA:MNRT
|
0.010x |
|
Xilinmen Furniture Co Ltd
SHG:603008
|
0.044x |
|
BEH Property Co Ltd
SHG:600791
|
0.055x |
Annual Cash Flow Conversion Efficiency for Valneva SE (2005–2025)
The table below shows the annual cash flow conversion efficiency of Valneva SE from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Valneva SE market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €106.17 Million ≈ $124.12 Million |
€-52.89 Million ≈ $-61.84 Million |
-0.498x | -34.34% |
| 2024-12-31 | €181.25 Million ≈ $211.90 Million |
€-67.22 Million ≈ $-78.58 Million |
-0.371x | +76.54% |
| 2023-12-31 | €128.25 Million ≈ $149.93 Million |
€-202.74 Million ≈ $-237.03 Million |
-1.581x | -41.63% |
| 2022-12-31 | €219.80 Million ≈ $256.97 Million |
€-245.34 Million ≈ $-286.83 Million |
-1.116x | -347.60% |
| 2021-12-31 | €170.58 Million ≈ $199.43 Million |
€76.90 Million ≈ $89.91 Million |
0.451x | -74.66% |
| 2020-12-31 | €77.42 Million ≈ $90.51 Million |
€137.74 Million ≈ $161.03 Million |
1.779x | +4248.79% |
| 2019-12-31 | €135.15 Million ≈ $158.01 Million |
€5.53 Million ≈ $6.46 Million |
0.041x | -64.08% |
| 2018-12-31 | €143.19 Million ≈ $167.40 Million |
€16.31 Million ≈ $19.06 Million |
0.114x | -17.74% |
| 2017-12-31 | €92.67 Million ≈ $108.34 Million |
€12.83 Million ≈ $15.00 Million |
0.138x | +112.93% |
| 2016-12-31 | €100.05 Million ≈ $116.97 Million |
€6.50 Million ≈ $7.61 Million |
0.065x | +138.56% |
| 2015-12-31 | €144.34 Million ≈ $168.74 Million |
€-24.33 Million ≈ $-28.45 Million |
-0.169x | -40.39% |
| 2014-12-31 | €124.44 Million ≈ $145.49 Million |
€-14.94 Million ≈ $-17.47 Million |
-0.120x | +17.21% |
| 2013-12-31 | €144.11 Million ≈ $168.48 Million |
€-20.90 Million ≈ $-24.44 Million |
-0.145x | +71.26% |
| 2012-12-31 | €26.19 Million ≈ $30.62 Million |
€-13.22 Million ≈ $-15.46 Million |
-0.505x | -135.82% |
| 2011-12-31 | €40.45 Million ≈ $47.28 Million |
€-8.66 Million ≈ $-10.12 Million |
-0.214x | -200.52% |
| 2010-12-31 | €44.29 Million ≈ $51.78 Million |
€-3.15 Million ≈ $-3.69 Million |
-0.071x | -270.86% |
| 2009-12-31 | €22.53 Million ≈ $26.34 Million |
€939.00K ≈ $1.10 Million |
0.042x | +162.04% |
| 2008-12-31 | €27.42 Million ≈ $32.05 Million |
€-1.84 Million ≈ $-2.15 Million |
-0.067x | +45.33% |
| 2007-12-31 | €29.01 Million ≈ $33.92 Million |
€-3.56 Million ≈ $-4.17 Million |
-0.123x | +79.07% |
| 2006-12-31 | €4.66 Million ≈ $5.45 Million |
€-2.73 Million ≈ $-3.20 Million |
-0.587x | -511.87% |
| 2005-12-31 | €4.78 Million ≈ $5.59 Million |
€681.00K ≈ $796.16K |
0.143x | -- |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more